Roche 1st-qtr 2011 sales in line with consensus forecasts

14 April 2011

Swiss drug major Roche (ROG: VX) has reported first-quarter 2011 sales in-line with consensus estimates, and reiterated guidance for fiscal year 2011. Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) were 11.1 billion Swiss francs ($12.18 billion) in first three months of 2011. Excluding flu drug Tamiflu (oseltamivir), which slumped 47% year-on-year to 252 million francs, group sales rose 2% (-7% in Swiss francs, +4% in US dollars). Roche did not publish earnings at this point.

Commenting on the Group’s first-quarter 2011 performance, Roche chief executive Severin Schwan said: ‘Based on our first-quarter sales, we are on track to achieve our targets for the full-year. And since the beginning of the year we have already announced positive results from seven key Phase II or III clinical trials, further underscoring our growth prospects for the coming years.’

Pharma sales dip 2%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK